These VCs don’t wait for biotech startups to come to them. They create companies themselves.
Antonio RegaladoFollow @twitterapi
Senior Editor, Business
I am the business editor of MIT Technology Review. I look for stories about how technology is changing business. Before joining MIT Technology Review in July 2011, I lived in São Paulo, Brazil, where I wrote about science, technology, and politics in Latin America for Science and other publications. From 2000 to 2009, I was the science reporter at the Wall Street Journal and later a foreign correspondent.
Antonio Regalado's Stories
Researchers find a way to turn pain on, and off, with a beam of light.
In danger of being left behind on the Web, big publishers jump on the data science bandwagon.
Claims for a new, simple, technique to create stem cells.
A cutting-edge corner of science is being wooed by Silicon Valley, to the dismay of some academics.
Officials have charged another Bitcoin entrepreneur with money laundering.
Optimization technology is reshaping publishers’ decision-making process—and the Web itself.
What’s the point of all that data, anyway? It’s to make decisions.
IBM says it will invest $1 billion in the computer system that won on Jeopardy! but has stumbled so far in the real world.
A bubble formed around social media in 2013. But other companies, nations, and ordinary people struggled to find advantage in technological change.